Encorafenib

Major

Encorafenib Tacrolimus Astagraf Reduced CYP3A4 substrate exposure, reduced efficacy of CYP3A4 substrate and an increased risk of QT interval prolongation Details Encorafenib Taletrectinib Ibtrozi Reduced taletrectinib exposure, reduced efficacy of taletrectinib, increased risk of QT interval prolongation, and torsade de poin... Details Encorafenib Tamoxifen Nolvadex® Increased risk of QT interval prolongation Details Encorafenib Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Encorafenib Telaprevir Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions and an increased risk of QT interval pr... Details Encorafenib Telavancin Vibativ Increased risk of QT interval prolongation Details Encorafenib Telithromycin Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions and an increased risk of QT interval pr... Details Encorafenib Temsirolimus Torisel Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Tetrabenazine Xenazine Increased risk of QT interval prolongation Details Encorafenib Ticagrelor Brilinta Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Tipranavir Aptivus Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Tolterodine Detrol Increased risk of QT interval prolongation Details Encorafenib Tolvaptan Jynarque Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Toremifene Fareston Increased risk of QT interval prolongation Details Encorafenib Trabectedin Yondelis Reduced trabectedin exposure Details Encorafenib Tramadol ConZip Reduced traMADol exposure and reduced efficacy of traMADol Details Encorafenib Trazodone Raldesy Increased risk of QT interval prolongation Details Encorafenib Triazolam Halcion Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Triclabendazole Egaten An increased risk of QT interval prolongation Details Encorafenib Trimipramine Increased risk of QT interval prolongation Details Encorafenib Triptorelin Increased risk of QT interval prolongation Details Encorafenib Troleandomycin Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Tucatinib Tukysa Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Ubrogepant Ubrelvy Altered (increased or reduced) ubrogepant exposure, an increased risk of ubrogepant-related toxicities and reduced efficacy of ubr... Details Encorafenib Ulipristal Ella Reduced hormonal contraceptives exposure and reduced efficacy of hormonal contraceptives Details Encorafenib Vandetanib Caprelsa Increased risk of QT interval prolongation Details Encorafenib Vardenafil Levitra Reduced CYP3A4 substrate exposure, reduced efficacy of CYP3A4 substrate and an increased risk of QT interval prolongation Details Encorafenib Vemurafenib Zelboraf Increased risk of QT interval prolongation Details Encorafenib Venetoclax Venclexta Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Venlafaxine Increased risk of QT interval prolongation Details Encorafenib Vepdegestrant Veppanu Reduced vepdegestrant exposure, reduced efficacy of vepdegestrant, an increased risk of QT interval prolongation and an increased... Details Encorafenib Verapamil Calan Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Vilanterol Increased risk of QT interval prolongation Details Encorafenib Vinflunine Increased risk of QT interval prolongation Details Encorafenib Voclosporin Lupkynis Reduced voclosporin exposure, reduced efficacy of voclosporin and an increased risk of QT interval prolongation and torsade de poi... Details Encorafenib Voriconazole Vfend Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions and an increased risk of QT interval pr... Details Encorafenib Vorinostat Zolinza Increased risk of QT interval prolongation Details Encorafenib Voxelotor Oxbryta Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Encorafenib Zanubrutinib Brukinsa Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Encorafenib Ziftomenib Komzifti An increased risk of QT interval prolongation, reduced ziftomenib exposure and reduced efficacy of ziftomenib Details